Hope for dogs with with a cellular therapeutic targeted to the underlying cause

We need your help

Do you have canine patients diagnosed with osteoarthritis (OA) of two or more joints based on radiographic assessment?

If so, those patients may be eligible for a pivotal study to support FDA-approval of an allogeneic, ready-to-use stem cell therapy for control of their clinical signs associated with OA.


  • Stem cells offer a treatment option for dogs with osteoarthritis
  • Your client’s dog will receive specialty veterinary care throughout the study, including physical exams, radiographs, blood work, and urinalysis at NO OUT-OF-POCKET cost to the pet parent.
  • You and your client’s dog may play an important role in advancing canine medicine.

This study may be used to support a new animal drug application to be submitted to the Food and Drug Administration.

Why Stem Cells?

Stem cells are naturally occurring cells that exist in adult tissues and have regenerative properties (help tissues repair). These stem cells have the ability to immunomodulate (regulation of the immune system to be adaptive) through cellular signaling. This provides a natural and targeted mechanism for treatment of the underlying disease.

The mesenchymal stem cells (MSCs) used in this product are derived from a healthy donor dog’s uterus that is collected during a routine spay procedure. The cells are harvested, cultured, expanded, and frozen to provide a source of live cells once thawed at the time of treatment.

There have been multiple studies demonstrating the ability of adult mesenchymal stem cells to improve clinical status of canine patients suffering from OA. Several studies have investigated mesenchymal stem cells in other canine diseases; including spinal disk herniation, kidney disease, and inflammatory bowel disease.

Interested in Participating in the Clinical Trial?